Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

27.57
-1.3000-4.50%
Post-market: 27.700.1300+0.47%19:52 EDT
Volume:784.51K
Turnover:21.73M
Market Cap:3.13B
PE:-11.09
High:28.77
Open:28.45
Low:27.40
Close:28.87
52wk High:30.06
52wk Low:8.67
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.68
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:5.96
PE(LYR):-11.34

Loading ...

Immunome Price Target Maintained With a $31.00/Share by Wedbush

Dow Jones
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

TIPRANKS
·
Jun 12

Craig-Hallum Sticks to Its Buy Rating for Immunome (IMNM)

TIPRANKS
·
Jun 11

Immunome doses first patient in Phase 1 trial of IM-1617 solid-tumor ADC

Reuters
·
Jun 11

Immunome - Plans Ind Submission for IM-1340 in Mid-2026 and IM-1335 in Late 2026

THOMSON REUTERS
·
Jun 11

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients With Advanced Solid Tumors

THOMSON REUTERS
·
Jun 11

Immunome director Jean Jacques Bienaime sells USD 203,820 of common shares

Reuters
·
Jun 10

Immunome grants 353,000 inducement stock options to new hires at USD 20.78 strike price

Reuters
·
Jun 05

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

GlobeNewswire
·
Jun 03

Wedbush Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Jun 01

Lake Street Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Jun 01

Immunome announces Ringside trial met primary, secondary endpoints

TIPRANKS
·
May 31

A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage

Simply Wall St.
·
May 31

Immunome - Varegacestat Treatment Resulted in Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints

THOMSON REUTERS
·
May 30

Immunome says FDA reviews varegacestat NDA for desmoid tumors

Reuters
·
May 30

Immunome says Phase 3 RINGSIDE trial shows varegacestat cuts desmoid tumor progression or death risk 84%

Reuters
·
May 30

Immunome Is Maintained at Buy by Truist Securities

Dow Jones
·
May 29

Immunome price target raised to $37 from $36 at Truist

TIPRANKS
·
May 28

Immunome Initiated at Overweight by Barclays

Dow Jones
·
May 28

Barclays Initiates Immunome at Overweight With $36 Price Target

MT Newswires Live
·
May 28